文献

J-GLOBAL ID：202202236176499799   整理番号：22A0808091

進行肝細胞癌患者における分子標的薬の生存影響の進化【JST・京大機械翻訳】

Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma

著者 (46件)： Kobayashi Kazufumi (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Kobayashi Kazufumi (Translational Research and Development Center, Chiba University Hospital, Chiba, Japan) ,  Ogasawara Sadahisa (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Ogasawara Sadahisa (Translational Research and Development Center, Chiba University Hospital, Chiba, Japan) ,  Takahashi Aya (Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan) ,  Seko Yuya (Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan) ,  Unozawa Hidemi (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Sato Rui (Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan) ,  Watanabe Shunji (Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan) ,  Moriguchi Michihisa (Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan) ,  Morimoto Naoki (Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan) ,  Tsuchiya Satoshi (Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan) ,  Iwai Kenji (Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan) ,  Inoue Masanori (Numazu City Hospital, Shizuoka, Japan) ,  Ogawa Keita (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Ishino Takamasa (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Iwanaga Terunao (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Sakuma Takafumi (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Fujita Naoto (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Kanzaki Hiroaki (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Koroki Keisuke (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Nakamura Masato (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Kanogawa Naoya (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Kiyono Soichiro (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Kondo Takayuki (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Saito Tomoko (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Nakagawa Ryo (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Suzuki Eiichiro (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Ooka Yoshihiko (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Nakamoto Shingo (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Tawada Akinobu (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Tawada Akinobu (Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Chiba Tetsuhiro (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Arai Makoto (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Arai Makoto (Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Kanda Tatsuo (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Kanda Tatsuo (Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan) ,  Maruyama Hitoshi (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Maruyama Hitoshi (Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan) ,  Nagashima Kengo (Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tokyo, Japan) ,  Nagashima Kengo (Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan) ,  Kato Jun (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan) ,  Isoda Norio (Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan) ,  Aramaki Takeshi (Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan) ,  Itoh Yoshito (Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan) ,  Kato Naoya (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan)
資料名： Liver Cancer  (Liver Cancer)
巻： 11  号： 1  ページ： 48-60  発行年： 2022年 
JST資料番号： W6341A  ISSN： 2235-1795  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： スイス (CHE)  言語： 英語 (EN)

抄録/ポイント： 背景と目的:進行肝細胞癌(HCC)患者の予後は,複数の分子標的薬剤(MTA)が現在利用可能であると予想される。しかし,逐次MTAの利用可能性の影響は,まだ完全には検証されていない。方法および結果:2009年6月~2019年3月の間に進行HCCに対する第一選択全身療法としてMTAを投与された患者877名の全臨床経過に関するデータを遡及的に収集した。研究集団を第1選択MTA投与(期間1:2009~2012,n=267;期間2:2013~2016,n=352;期間3:2017~2019,n=258)に従って3群に分けた。次に,3群間で使用したMTAの数,全生存率(OS)およびMTA治療期間を比較した。分析はまた,進行期および非進行期HCCに対して別々に行った。多発性MTAを受けた患者の割合は,時間とともに著しく増加した(それぞれ,1.1%,10.2%,および42.6%,2,および3,p<0.001)。OS時間の中央値は,それぞれ10.4,11.3,および15.2か月に,1,2,および3で延長した(p=0.016)。同様に,MTA治療期間は延長された(それぞれ,2.7,3.2および6.6か月,1,2および3,p<0.001)。OSとMTA治療期間の相関が強化された(期間1:0.395,期間2:0.505,期間3:0.667)。これらの傾向はすべて進行期HCC患者で顕著であったが,非進行性HCC患者では限定された。結論:多発性MTAの有用性は,進行性HCC患者,特に進行期HCC患者の予後を着実に改善した。Please refer to the publisher for the copyright holders. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 比率 ,  期間 ,  生存率 ,  治療法 ,  病状経過 ,  *肝細胞癌 ,  *進行癌 ,  *分子標的治療薬
準シソーラス用語： 治療期間 ,  進行期 ,  *進行肝細胞癌 ,  全生存率 ,  全身療法 ,  患者予後 ,  ラムシルマブ , 【Automatic Indexing@JST】

著者キーワード (5件)： 逐次療法 ,  ソラフェニブ ,  レゴラフェニブ ,  レンバチニブ ,  ラムシルマブ

分類 (2件)： 腫ようの薬物療法  (GE03032C) ,  消化器の腫よう  (GH04000D)

物質索引 (2件)： ソラフェニブ ,  レゴラフェニブ

タイトルに関連する用語 (5件)： 進行肝細胞癌 ,  患者 ,  分子標的薬 ,  生存 ,  進化